Carney W - Search Results

1

The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.

Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H. Schippinger W, et al. Among authors: carney w. Oncol Rep. 2004 Jun;11(6):1331-6. Oncol Rep. 2004. PMID: 15138574

2

Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.

Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Carney WP, et al. Clin Chem. 2003 Oct;49(10):1579-98. doi: 10.1373/49.10.1579. Clin Chem. 2003. PMID: 14500583 Review.

3

Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.

Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Carney WP, et al. Clin Breast Cancer. 2004 Jun;5(2):105-16. doi: 10.3816/cbc.2004.n.014. Clin Breast Cancer. 2004. PMID: 15245613 Review.

4

HER-2/neu diagnostics in breast cancer.

Carney WP, Leitzel K, Ali S, Neumann R, Lipton A. Carney WP, et al. Breast Cancer Res. 2007;9(3):207. doi: 10.1186/bcr1664. Breast Cancer Res. 2007. PMID: 17561991 Free PMC article.

5

Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.

Bethune-Volters A, Labroquere M, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF. Bethune-Volters A, et al. Among authors: carney w. Anticancer Res. 2004 Mar-Apr;24(2C):1083-9. Anticancer Res. 2004. PMID: 15154627 Free article.

6

Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.

Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF. Pallud C, et al. Among authors: carney w. Anticancer Res. 2005 Mar-Apr;25(2B):1433-40. Anticancer Res. 2005. PMID: 15865102 Free article.

7

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.

Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J. Lipton A, et al. Among authors: carney w. J Clin Oncol. 2002 Mar 15;20(6):1467-72. doi: 10.1200/JCO.2002.20.6.1467. J Clin Oncol. 2002. PMID: 11896093 Clinical Trial.

8

Hidden HER-2/neu-positive breast cancer: how to maximize detection.

Carney WP. Carney WP. IDrugs. 2009 Apr;12(4):238-42. IDrugs. 2009. PMID: 19350468 Review.

9

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.

Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hösch S, Hayes DF. Yamauchi H, et al. Among authors: carney w. J Clin Oncol. 1997 Jul;15(7):2518-25. doi: 10.1200/JCO.1997.15.7.2518. J Clin Oncol. 1997. PMID: 9215820

10

Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.

Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W. Lipton A, et al. Among authors: carney w. J Clin Oncol. 2003 May 15;21(10):1967-72. doi: 10.1200/JCO.2003.09.098. J Clin Oncol. 2003. PMID: 12743150 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

171 results

Search Page

Filters